Gilead grabs Roche vet as CEO

Dec 10, 2018

Gilead Sciences has named Roche Holding's Daniel O’Day as its new chief executive.

O’Day, now head of Roche’s pharmaceuticals business, joined the company in 1987 and held various roles in the U.S. before moving in 1998 to headquarters in Basel, Switzerland.

Gilead is hoping that O’Day’s three decades of oncology and global commercial expertise at Roche will help the company build out its global presence, particularly in oncology and inflammation.

As previously announced, Gilead’s CEO John Milligan and Chairman John Martin will step down at the end of the year.

Read the press release

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments